Pharmacological Preventive Potential Among Attenders at Vascular Screening: Findings from the VIVA Trial

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Pharmacological Preventive Potential Among Attenders at Vascular Screening : Findings from the VIVA Trial. / Hansen, Tina B; Søgaard, Rikke; Lindholt, Jes S.

I: European Journal of Vascular and Endovascular Surgery, Bind 59, Nr. 4, 2020, s. 662-673.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Hansen, TB, Søgaard, R & Lindholt, JS 2020, 'Pharmacological Preventive Potential Among Attenders at Vascular Screening: Findings from the VIVA Trial', European Journal of Vascular and Endovascular Surgery, bind 59, nr. 4, s. 662-673. https://doi.org/10.1016/j.ejvs.2019.12.039

APA

CBE

MLA

Hansen, Tina B, Rikke Søgaard, og Jes S Lindholt. "Pharmacological Preventive Potential Among Attenders at Vascular Screening: Findings from the VIVA Trial". European Journal of Vascular and Endovascular Surgery. 2020, 59(4). 662-673. https://doi.org/10.1016/j.ejvs.2019.12.039

Vancouver

Author

Hansen, Tina B ; Søgaard, Rikke ; Lindholt, Jes S. / Pharmacological Preventive Potential Among Attenders at Vascular Screening : Findings from the VIVA Trial. I: European Journal of Vascular and Endovascular Surgery. 2020 ; Bind 59, Nr. 4. s. 662-673.

Bibtex

@article{b125d2b9c9114a859729947ce16ac7f5,
title = "Pharmacological Preventive Potential Among Attenders at Vascular Screening: Findings from the VIVA Trial",
abstract = "OBJECTIVE: Findings from the Viborg Vascular (VIVA) trial show a mortality benefit of multi-faceted vascular screening which was mainly ascribed to the initiation of prophylactic medication. However, the pharmacological preventive potential, which exists when individuals have a positive screening test result and do not already use statins and anti-platelet agents, has not been analysed. The aim of this study was to investigate factors associated with a pharmacological preventive potential of statins and anti-platelet agents among attenders vascular screening for abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD).METHODS: This cross-sectional study used data from the VIVA trial screening arm including 25 074 men aged 64-75 years recruited between October 2008 and January 2011. Explanatory variables comprised socio-demographic- and socio-economic characteristics, comorbidities, medication use, and travel distance derived from nationwide registries. Outcomes included a positive screening test result, a pharmacological preventive potential, and attendance. Associations between the explanatory variables and the outcomes were investigated using the chi-square test and multivariate logistic regression.RESULTS: The factors most likely to be associated with a pharmacological preventive potential for positive AAA screening comprised age >70 years (odds ratio (OR) 1.23, 95% confidence interval 1.00-1.51), existing chronic obstructive pulmonary disease (COPD) (OR 2.22, 95% CI 1.38-3.57), and use of anti-hypertensives (OR 1.37, 95% CI 1.09-1.71). For positive PAD screening age >70 years (OR 1.41, 95% CI 1.25-1.60), living alone (OR 1.34, 95% CI 1.14-1.56), low income, COPD (OR 2.13, 95% CI 159-283), use of anti-hypertensives (OR 1.14, 95% CI 1.00-1.29) or anti-diabetics (OR 1.12, 95% CI 1.01-1.28), and short travel distance were associated with a pharmacological preventive potential. For combined vascular screening, age >70 years, living alone, low income, COPD, and use of anti-hypertensives were associated with a pharmacological preventive potential. Among these subgroups, lower attendance was associated with age >70 years, living alone, low income, COPD, and use of anti-diabetics.CONCLUSION: Future vascular screening programmes might benefit from tailoring information to subgroups who are more likely to benefit from screening but less likely to accept an offer.",
keywords = "Abdominal aortic aneurysm, Peripheral arterial disease, Screening, Secondary prevention, Vascular disease",
author = "Hansen, {Tina B} and Rikke S{\o}gaard and Lindholt, {Jes S}",
note = "Copyright {\textcopyright} 2020 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.",
year = "2020",
doi = "10.1016/j.ejvs.2019.12.039",
language = "English",
volume = "59",
pages = "662--673",
journal = "European Journal of Vascular and Endovascular Surgery",
issn = "1078-5884",
publisher = "Elsevier Ltd",
number = "4",

}

RIS

TY - JOUR

T1 - Pharmacological Preventive Potential Among Attenders at Vascular Screening

T2 - Findings from the VIVA Trial

AU - Hansen, Tina B

AU - Søgaard, Rikke

AU - Lindholt, Jes S

N1 - Copyright © 2020 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.

PY - 2020

Y1 - 2020

N2 - OBJECTIVE: Findings from the Viborg Vascular (VIVA) trial show a mortality benefit of multi-faceted vascular screening which was mainly ascribed to the initiation of prophylactic medication. However, the pharmacological preventive potential, which exists when individuals have a positive screening test result and do not already use statins and anti-platelet agents, has not been analysed. The aim of this study was to investigate factors associated with a pharmacological preventive potential of statins and anti-platelet agents among attenders vascular screening for abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD).METHODS: This cross-sectional study used data from the VIVA trial screening arm including 25 074 men aged 64-75 years recruited between October 2008 and January 2011. Explanatory variables comprised socio-demographic- and socio-economic characteristics, comorbidities, medication use, and travel distance derived from nationwide registries. Outcomes included a positive screening test result, a pharmacological preventive potential, and attendance. Associations between the explanatory variables and the outcomes were investigated using the chi-square test and multivariate logistic regression.RESULTS: The factors most likely to be associated with a pharmacological preventive potential for positive AAA screening comprised age >70 years (odds ratio (OR) 1.23, 95% confidence interval 1.00-1.51), existing chronic obstructive pulmonary disease (COPD) (OR 2.22, 95% CI 1.38-3.57), and use of anti-hypertensives (OR 1.37, 95% CI 1.09-1.71). For positive PAD screening age >70 years (OR 1.41, 95% CI 1.25-1.60), living alone (OR 1.34, 95% CI 1.14-1.56), low income, COPD (OR 2.13, 95% CI 159-283), use of anti-hypertensives (OR 1.14, 95% CI 1.00-1.29) or anti-diabetics (OR 1.12, 95% CI 1.01-1.28), and short travel distance were associated with a pharmacological preventive potential. For combined vascular screening, age >70 years, living alone, low income, COPD, and use of anti-hypertensives were associated with a pharmacological preventive potential. Among these subgroups, lower attendance was associated with age >70 years, living alone, low income, COPD, and use of anti-diabetics.CONCLUSION: Future vascular screening programmes might benefit from tailoring information to subgroups who are more likely to benefit from screening but less likely to accept an offer.

AB - OBJECTIVE: Findings from the Viborg Vascular (VIVA) trial show a mortality benefit of multi-faceted vascular screening which was mainly ascribed to the initiation of prophylactic medication. However, the pharmacological preventive potential, which exists when individuals have a positive screening test result and do not already use statins and anti-platelet agents, has not been analysed. The aim of this study was to investigate factors associated with a pharmacological preventive potential of statins and anti-platelet agents among attenders vascular screening for abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD).METHODS: This cross-sectional study used data from the VIVA trial screening arm including 25 074 men aged 64-75 years recruited between October 2008 and January 2011. Explanatory variables comprised socio-demographic- and socio-economic characteristics, comorbidities, medication use, and travel distance derived from nationwide registries. Outcomes included a positive screening test result, a pharmacological preventive potential, and attendance. Associations between the explanatory variables and the outcomes were investigated using the chi-square test and multivariate logistic regression.RESULTS: The factors most likely to be associated with a pharmacological preventive potential for positive AAA screening comprised age >70 years (odds ratio (OR) 1.23, 95% confidence interval 1.00-1.51), existing chronic obstructive pulmonary disease (COPD) (OR 2.22, 95% CI 1.38-3.57), and use of anti-hypertensives (OR 1.37, 95% CI 1.09-1.71). For positive PAD screening age >70 years (OR 1.41, 95% CI 1.25-1.60), living alone (OR 1.34, 95% CI 1.14-1.56), low income, COPD (OR 2.13, 95% CI 159-283), use of anti-hypertensives (OR 1.14, 95% CI 1.00-1.29) or anti-diabetics (OR 1.12, 95% CI 1.01-1.28), and short travel distance were associated with a pharmacological preventive potential. For combined vascular screening, age >70 years, living alone, low income, COPD, and use of anti-hypertensives were associated with a pharmacological preventive potential. Among these subgroups, lower attendance was associated with age >70 years, living alone, low income, COPD, and use of anti-diabetics.CONCLUSION: Future vascular screening programmes might benefit from tailoring information to subgroups who are more likely to benefit from screening but less likely to accept an offer.

KW - Abdominal aortic aneurysm

KW - Peripheral arterial disease

KW - Screening

KW - Secondary prevention

KW - Vascular disease

UR - http://www.scopus.com/inward/record.url?scp=85079518484&partnerID=8YFLogxK

U2 - 10.1016/j.ejvs.2019.12.039

DO - 10.1016/j.ejvs.2019.12.039

M3 - Journal article

C2 - 32063462

VL - 59

SP - 662

EP - 673

JO - European Journal of Vascular and Endovascular Surgery

JF - European Journal of Vascular and Endovascular Surgery

SN - 1078-5884

IS - 4

ER -